Elevance Health Inc.'s Stock Analysis

Elevance Health Issues $2.97 Billion in New Notes

Elevance Health, Inc. has completed the sale of $2.97 billion in new notes, including $750 million of 4.000% notes due 2028, $750 million of 4.600% notes due 2032, $1 billion of 5.000% notes due 2036, and $500 million of 5.700% notes due 2055. These notes were issued under an underwriting agreement and have been registered under the Securities Act. The company intends to use the proceeds primarily to repay existing senior notes and for general corporate purposes, including working capital and potential acquisitions.

The notes have various maturity dates ranging from 2028 to 2055, with interest payments scheduled semi-annually. The company has the option to redeem the notes before their maturity dates under specific conditions. Additionally, if a change of control occurs, and the notes are downgraded below investment grade, the company is obligated to offer to purchase the notes at a premium. The issuance of these notes may impact the company's financial leverage and liquidity position, which are important factors for investors.

Sep 15, 2025 16:05:10

Elevance Health Reaffirms Earnings Guidance for 2025

Elevance Health, Inc. plans to engage with investors in the coming weeks, during which company officers will reaffirm the earnings guidance for the full year 2025. The expected earnings are approximately $24.10 per diluted share, which includes about $5.90 per diluted share of net unfavorable items. Excluding these items, the adjusted earnings guidance is approximately $30.00 per diluted share. Additionally, the company expects a benefit expense ratio of around 90.0% for the same period.

The company's guidance reflects current views on market conditions, operational performance, and key business assumptions. However, actual results may differ significantly if business factors or assumptions change. Investors are advised to consider various risks that could impact the company's performance, including healthcare cost trends, regulatory changes, competitive pressures, and potential cybersecurity issues. This information is important for understanding the potential risks and rewards associated with investing in Elevance Health.

Sep 04, 2025 06:02:07

Elevance Health Appoints Steve Collis as New Board Director

Elevance Health has elected Steven H. Collis as an independent director, effective August 1, 2025. He will serve a term that expires at the 2027 annual meeting and will also join the Audit and Finance Committees. Collis has been recognized as an audit committee financial expert and will receive standard compensation for his role as a director, as outlined in the company's existing compensation program for non-employee directors.

Steve Collis brings extensive experience in the healthcare sector, having previously served as the Executive Chairman of Cencora and as its President and CEO for 13 years. His appointment is part of Elevance Health's strategy to enhance governance and align board expertise with the company's growth objectives in a changing healthcare landscape. The board's decision reflects a commitment to evolving its membership to better address stakeholder needs and industry demands.

Jul 28, 2025 16:38:34

Elevance Health Reports Q2 2025 Financial Results and Guidance

Elevance Health, Inc. reported operating revenue of $49.4 billion for the second quarter of 2025, reflecting a 14.3% increase compared to the same quarter in 2024. The rise in revenue was attributed to higher premium yields in the Health Benefits segment, recent acquisitions, and growth in Medicare Advantage membership, though this was partially offset by membership attrition in the Medicaid business. The company reported a diluted earnings per share (EPS) of $7.72, with an adjusted diluted EPS of $8.84. The company has revised its full-year 2025 adjusted diluted EPS guidance to approximately $30.00, amid elevated medical cost trends in ACA and slower rate alignment in Medicaid.

As of June 30, 2025, Elevance Health had operating cash flow of $3.1 billion, with cash and investments at the parent company totaling approximately $2.2 billion. The company repurchased 0.9 million shares for $379 million during the second quarter and declared a quarterly dividend of $1.71 per share, payable on September 25, 2025. The Health Benefits segment generated $41.6 billion in operating revenue, while Carelon's revenue was $18.1 billion, a 36% increase year-over-year. Overall, the company aims for at least 12% average annual growth in adjusted diluted EPS over time, supported by its diversified business segments.

Jul 17, 2025 06:03:40

Company Discloses Risks and Challenges in Financial Performance

The press release outlines various risks and uncertainties that could affect the company's financial performance, including trends in healthcare costs, reduced enrollment, and the impact of regulatory changes. It highlights concerns related to competition, the ability to secure premium rates, and potential cybersecurity incidents as significant challenges the company may face moving forward.

On the positive side, the company emphasizes its commitment to maintaining and improving its quality scores and the importance of its relationships with providers. It also notes the potential for growth through strategic alliances and the ongoing evaluation of its operational capabilities to adapt to industry changes, indicating a focus on long-term sustainability.

Mar 10, 2025 16:17:17

Elevance Health Reports $45 Billion Q4 Revenue and EPS Drop

Elevance Health, Inc. reported operating revenue of $45.0 billion for the fourth quarter of 2024, marking a 6% increase year-over-year. The full year operating revenue reached $175.2 billion, up 3% from the previous year. The company also increased its quarterly dividend by 5% to $1.71 per share, reflecting a commitment to returning value to shareholders. Adjusted diluted earnings per share (EPS) for the fourth quarter was $3.84, while the full year adjusted EPS stood at $33.04, indicating a solid performance amidst operational challenges.

Conversely, the company faced a decline in operating gain for the fourth quarter, which fell to $0.7 billion, a 46% decrease from the prior year. The benefit expense ratio increased to 92.4% in Q4, driven by rising Medicaid medical costs, contributing to a decline in net income by 51% to $418 million compared to the previous year. Additionally, medical membership decreased by 2% year-over-year, largely due to attrition in the Medicaid segment, which could pose challenges for future growth.

Jan 23, 2025 06:03:24

Elevance Health Reports Strong Q3 2024 Earnings Results

Elevance Health, Inc. reported positive third quarter results for 2024, showcasing an operating revenue of $44.7 billion, up from $42.5 billion the previous year. The company achieved an adjusted operating gain of $2.4 billion and declared a quarterly dividend of $1.63 per share, reflecting a commitment to returning value to shareholders. The growth in revenue was largely attributed to increased premium yields and expansion in CarelonRx product revenue, despite some challenges in the Medicaid segment due to membership attrition. The operating expense ratio improved, indicating effective cost management strategies in place.

However, the company faced challenges in its Medicaid business, with a significant drop in medical membership, particularly due to eligibility redeterminations. The benefit expense ratio increased, which may indicate rising costs associated with providing care. Additionally, net income attributable to shareholders decreased by 21.2% compared to the previous year, highlighting some underlying pressures despite the overall positive revenue growth. The management expressed confidence in the company's long-term potential while navigating these operational challenges.

Oct 17, 2024 06:02:29

Elevance Health Reports Positive Second Quarter 2024 Results

Elevance Health reported a 2Q 2024 operating revenue of $43.2 billion, with adjusted operating gain up to $2.8 billion and diluted EPS up by 26%. The company declared a 3Q 2024 dividend of $1.63 per share. Despite a slight decrease in operating revenue, the company highlighted growth in CarelonRx product revenue. Elevance Health aims for a strong full-year outlook with confidence in its businesses. The company also repurchased shares and maintained a healthy balance sheet with $2.4 billion in cash and investments.

Jul 17, 2024 06:09:34

Elevance Health, Inc. Reaffirms 2024 Net Income Guidance

Elevance Health, Inc. officers will reaffirm the company's net income guidance for 2024, expecting adjusted net income to be greater than $37.20 per diluted share. The guidance excludes certain adjustment items. The company warns about risks and uncertainties, urging caution when considering forward-looking statements. Factors like healthcare trends, regulations, and cybersecurity incidents could impact the business. Elevance Health, Inc. also mentions risks related to financial strength, competition, and international operations in their communications with investors.

Jun 12, 2024 06:07:00

Elevance Health Reports Positive First Quarter 2024 Results and Strategic Partnership

Elevance Health's 1Q 2024 revenue increased by 0.9%, diluted EPS rose by 15.5%, and adjusted diluted EPS grew by 12.5%. FY 2024 EPS guidance raised. A strategic partnership with Clayton, Dubilier & Rice aims to enhance primary care and physician enablement. Operating revenue increased driven by higher premium yields and Carelon growth, offset by Medicaid membership attrition. Cash flow was strong, with $2.0 billion operating cash flow and $1.0 billion in cash and investments. Share repurchases and dividends were notable.

Apr 18, 2024 06:07:53